drug

lubiprostone

Marketedupdated 2mo ago

by Mallinckrodt LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 23, 2027

200 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Oct 25, 2027formulationUS 80263931.3y
Oct 25, 2027formulationUS 80263931.3y
Jan 23, 2027formulationUS 8338639200d
Jan 23, 2027formulationUS 8338639200d
Jan 23, 2027formulationUS 8779187200d
Jan 23, 2027formulationUS 8779187200d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 31m ago

Found something off?

Trials studying lubiprostone

—Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipationrecruitingn=34,532
phase4Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparationcompletedn=158